Advanced search
Publication Cover
Hematology Volume 27, 2022 - Issue 1
Submit an article Journal homepage
3,060
Views
2
CrossRef citations to date
0
Altmetric
Research Article

Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study

Faouzi Djebbaria Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9578-7632
ORCID Icon,
Alexandros Rampotasa Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK;d Oxford University Clinical Academic Graduate School, Oxford, UK
,
Grant Vallancea Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
,
Fotios Panitsasc Department of Haematology, Laiko General Hospital, Athens, Greece
,
Nanda Baskerb University Hospital Southampton, Southampton, UK
,
Gina Sanghae Milton Keynes Hospital, Milton Keynes, UK
,
Beena Salhanf Birmingham Heartlands Hospital, Birmingham, UK;g Good Hope Hospital, Birmingham, UK;h Solihull Hospital, Solihull, UK;i West Midlands Research Consortium (WMRC), West Midlands, UK
,
Farheen Karimi West Midlands Research Consortium (WMRC), West Midlands, UK;j The Royal Wolverhampton NHS Trust, Wolverhampton, UK
,
Al-Kaisi Firask Royal Derby Hospital, Derby, UK;aa Wexham Park Hospital, Slough, UK
,
Amy Gudgeri West Midlands Research Consortium (WMRC), West Midlands, UK;l Queen Elizabeth Hospital, Birmingham, UK;ab University of Wolverhampton, Wolverhampton, UK
,
Loretta Ngum Royal Devon & Exeter NHS Foundation Trust, Exeter, UK
,
Matt Poyntonn Royal Berkshire Hospital, Reading, UK
,
Ho Pui Jeff Lamo Guy's and St Thomas NHS Foundation Trust, London, UK
,
Lowri Morganp University Hospital of Wales, Cardiff, UK
,
Laura Yangq University Hospitals Sussex NHS Foundation Trust, Sussex, UK
,
Jennifer Youngr Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK
,
Mairi Walkers University Hospital Crosshouse, Crosshouse, UK
,
Ismini Tsagkarakit Stoke Mandeville Hospital, Aylesbury, UK
,
Laura Andersonu Royal United Hospital Bath, Bath, UK
,
Saleena Rani Chauhani West Midlands Research Consortium (WMRC), West Midlands, UK;v Worcestershire Acute Hospitals NHS Trust, Worcester, UK
,
Rebecca Maddamsw Poole Hospital, Poole, UK
,
Richard Soutarx Beatson Oncology Centre, Glasgow, UK
,
Margarita Triantafillouy Manchester Royal Infirmary, Manchester, UK
,
Steve Prideauxz Great Western Hospital, Swindon, UK
,
Abubaker Obeidallaaa Wexham Park Hospital, Slough, UK
,
Toby A. Eyrea Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
,
Ceri Bygravep University Hospital of Wales, Cardiff, UK
,
Supratik Basui West Midlands Research Consortium (WMRC), West Midlands, UK;j The Royal Wolverhampton NHS Trust, Wolverhampton, UK;ab University of Wolverhampton, Wolverhampton, UK
&
Karthik Ramasamya Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
 show all
Pages 691-699 | Published online: 06 Jun 2022

References

  • Augustson BM, Begum G, Dunn JA, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom medical research council trials between 1980 and 2002 – medical research council adult leukaemia working party. J Clin Oncology. 2005;23(36):9219–9226.
  • Blimark C, Holmberg E, Mellqvist UH, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015 Jan;100(1):107–113. DOI:10.3324/haematol.2014.107714. Epub 2014 Oct 24. PMID: 25344526; PMCID: PMC4281323.
  • Teh BW, Harrison SJ, Pellegrini M, et al. Changing treatment paradigms for patients with plasma cell myeloma: impact upon immune determinants of infection. Blood Rev. 2014;28(2):75–86.
  • Djebbari F, Panitsas F, Eyre TA, et al. Infection-related morbidity in a large study of transplant non-eligible newly diagnosed myeloma patients treated with UK standard of care. Haematologica. 2020 Sep 1;105(9):e474–e479. DOI:10.3324/haematol.2019.240762. PMID: 33054067; PMCID: PMC7556501.
  • Htut TW, Tun AM, Sultan A, et al. Updated meta-analysis of randomized controlled trials to evaluate the incidence of infection and pneumonia in patients with multiple myeloma treated with daratumumab. Blood. 2019;134(Suppl. 1):4771–4771. DOI:10.1182/blood-2019-123169.
  • Teh BW, Worth LJ, Harrison SJ, et al. Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian cancer hospital. Support Care Cancer. 2015 Jul;23(7):1901–1906. DOI:10.1007/s00520-014-2550-3. Epub 2014 Dec 10. PMID: 25487843; PMCID: PMC7087950.
  • Richardson PG, Beksaç M, Špička I, et al. Isatuximab for the treatment of relapsed/refractory multiple myeloma. Expert Opin Biol Ther. 2020;20(12):1395–1404. DOI:10.1080/14712598.2021.1841747.
  • National Institute for Health and Care Excellence. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma. 2020; [cited 2021 June 22]. Available from: https://www.nice.org.uk/guidance/TA658.
  • Attal M, Richardson PG, Vincent Rajkumar S, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394(10214):2096–2107. DOI:10.1016/S0140-6736(19)32556-5.
  • Shah JJ, Abonour R, Gasparetto C, et al. Analysis of common eligibility criteria of randomized controlled trials in newly diagnosed multiple myeloma patients and extrapolating outcomes. Clin Lymphoma Myeloma Leuk. 2017;17(9):572–583.
  • National Institute for Health and Care Excellence. COVID-19 rapid guideline: delivery of systemic anticancer treatments. 2020a; [cited 2020 Apr 21]. Available from: https://www.nice.org.uk/guidance/ng161/resources/covid19-rapid-guideline-delivery-of-systemic-anticancer-treatments-pdf-66141895710661.
  • Schjesvold F, Bringhen S, Richardson G, et al. Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. Am J Hematol. 2021;96:E423–E427. DOI:10.1002/ajh.26319.
  • Terpos E, Kleber M, Engelhardt M, et al. European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica. 2015 Oct;100(10):1254–1266. DOI:10.3324/haematol.2014.117176. PMID: 26432383; PMCID: PMC4591757.
  • Aleman A, Upadhyaya B, Tuballes K, et al. PVI/Seronet study group variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma. Cancer Cell. 2021;39:1442–1444.
  • Van Oekelen O, Gleason CR, Agte S, et al. PVI/Seronet team highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. Cancer Cell. 2021;39:1028–1030.
  • Aleman A, Van Oekelen O, Upadhyaya B, et al. Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients. Cancer Cell. 2022;40(5):441–443. Advance online publication. DOI:10.1016/j.ccell.2022.03.013.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.